New PET tracer spots hidden prostate cancer recurrence
NCT ID NCT04838613
First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 35 times
Summary
This study tested a new imaging agent called [18F]CTT1057 for PET scans to find prostate cancer that has come back after initial treatment. About 190 men with rising PSA levels (a sign of possible recurrence) took part. The goal was to see how accurately the scan could locate cancer in the body, using a standard reference to confirm findings.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Explorer Molecular Imaging center
Sacramento, California, 95816, United States
-
Novartis Investigative Site
Marseille, 13273, France
-
Novartis Investigative Site
Marseille, 13885, France
-
Novartis Investigative Site
Nîmes, 30029, France
-
Novartis Investigative Site
Pierre-Bénite, 69495, France
-
Novartis Investigative Site
Saint-Priest-en-Jarez, 42270, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, 08907, Spain
-
Novartis Investigative Site
Barcelona, Catalonia, 08035, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Barcelona, 08041, Spain
-
Novartis Investigative Site
Valencia, 46026, Spain
-
Novartis Investigative Site
Geneva, 1211, Switzerland
Conditions
Explore the condition pages connected to this study.